Cambridge, Mass., September 10, 2012 — Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative and orphan diseases, announced today that it will present at the Rodman & Renshaw 14th Annual
Cambridge, Mass., August 14, 2012 — Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative and orphan diseases, announced today that company scientists, founders and co-founders made the
Cambridge, Mass., July 26, 2012 — Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative and orphan diseases, announced today that it has expanded its collaboration with The Scripps Research
– Company to receive funding for novel therapies targeting Delta F508, most common CF mutation – Cambridge, Mass., May 7, 2012 — Proteostasis Therapeutics, Inc. (PTI), a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative
